NEW YORK (GenomeWeb News) – Bioanalytical tools company Hurel raised $9.2 million in a Series A private equity financing round, the North Brunswick, NJ-based company said today.

Proceeds from the round will go toward the commercial launch of Hurel's products, R&D work directed at its technologies and future products, and general corporate purposes, it said. Spring Mountain Capital led the round and was joined by undisclosed private investor entities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.